High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome

Circulation Journal

Volumn 78, Issue 10, 2014, Pages 2492-2500

  Van Nguyen, S ^a   Nakamura, Takamitsu ^a   Kugiyama, Kiyotaka ^a  

^a YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Acute coronary syndrome; Prognosis; Remnant lipoprotein; Statin

Indexed keywords

CREATINE KINASE MB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN; CHOLESTEROL; LIPOPROTEIN; REMNANT-LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; ANGINA, UNSTABLE; BLOOD; CLINICAL TRIAL; DEATH; MORTALITY; MYOCARDIAL INFARCTION; RISK FACTOR; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; CHOLESTEROL; DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 84908233363     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0380     Document Type: Article

References (28)

1. Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol 2000; 11: 615-620.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
3. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008; 101: 1003-1008.
4. Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380: 1482-1490.
5. Fox KA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H, et al. Underestimated and under-recognized: The late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31: 2755-2764.
6. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008; 51: 724-730.
7. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993; 223: 53-71.
8. Leary ET, Wang T, Baker DJ, Cilla DD, Zhong J, Warnick GR, et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem 1998; 44: 2490-2498.
9. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99: 2858-2860.
10. Nakamura T, Takano H, Umetani K, Kawabata K, Obata JE, Kitta Y, et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005; 181: 321-327.
11. Fukushima H, Sugiyama S, Honda O, Koide S, Nakamura S, Sakamoto T, et al. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol 2004; 43: 2219-2224.
12. Nakamura T, Obata JE, Takano H, Kawabata K, Sano K, Kobayashi T, et al. High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis. Atherosclerosis 2009; 202: 234-240.
13. Nakamura T, Obata JE, Hirano M, Kitta Y, Fujioka D, Saito Y, et al. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis 2011; 218: 163-167.
14. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee on the management of patients with unstable angina). Circulation 2000; 102: 1193-1209.
15. Lenfant C, Chobanian AV, Jones DW, Roccella EJ, Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): Resetting the hypertension sails. Hypertension 2003; 41: 1178-1179.
16. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 (Suppl 1): S15-S35.
17. JCS Joint Working Group. Guidelines for secondary prevention of myocardial infarction (JCS 2011): Digest version. Circ J 2013; 77: 231-248.
18. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan: 2012 version. J Atheroscler Thromb 2013; 20: 517-523.
19. Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000; 102: 670-676.
20. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e663-e828, doi:10.1161/CIR.0b013e31828478ac.
21. Tattersall MC, Gangnon RE, Karmali KN, Cullen MW, Stein JH, Keevil JG. Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: Longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys. PLoS One 2013; 8: e59309, doi:10.1371/journal.pone.0059309.
22. Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: Attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians’ Experience and Evaluation). Eur J Cardiovasc Prev Rehabil 2006; 13: 776-783.
23. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005; 28: 595-599.
24. Goldberg KC, Melnyk SD, Simel DL. Overcoming inertia: Improvement in achieving target low-density lipoprotein cholesterol. Am J Manag Care 2007; 13: 530-534.
25. Sano K, Nakamura T, Hirano M, Kitta Y, Kobayashi T, Fujioka D, et al. Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. Circ J 2010; 74: 1644-1650.
26. Kazama H, Usui S, Okazaki M, Hosoi T, Ito H, Orimo H. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res Clin Pract 2003; 59: 181-189.
27. Nakamura T, Hirano M, Kitta Y, Fujioka D, Saito Y, Kawabata K, et al. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol 2012; 60: 12-17.
28. Nochioka K, Tanaka S, Miura M, Zhulanqiqige do E, Fukumoto Y, Shiba N, et al. Ezetimibe improves endothelial function and inhibits Rho-kinase activity associated with inhibition of cholesterol absorption in humans. Circ J 2012; 76: 2023-2030.